Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CETROTIDE vs FIRMAGON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for assisted reproductive technology (ART)
FDA-approved for advanced prostate cancer (hormone-sensitive, metastatic or locally advanced),Off-label: Treatment of uterine fibroids, endometriosis, and precocious puberty
0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.
For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.
Terminal elimination half-life is approximately 36 hours after subcutaneous administration. This long half-life supports once-daily dosing for continuous Gn RH antagonist effect.
Terminal elimination half-life is approximately 63 days after subcutaneous administration in patients with prostate cancer, allowing for monthly dosing schedules.
Cetrorelix is metabolized via peptidase cleavage and is primarily eliminated unchanged in urine and feces.
Degraded into peptides and amino acids; not a substrate for CYP450 enzymes.
Primarily renal excretion of unchanged drug (approx. 40-50%) and metabolites; remainder excreted in feces via biliary elimination. Total recovery in urine and feces accounts for >90% of dose.
Primarily hepatobiliary; about 90% of the dose is eliminated in feces as unchanged drug, with less than 5% excreted renally as unchanged drug and metabolites.
Approximately 80% bound to plasma proteins, primarily albumin.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 0.7 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
Volume of distribution is approximately 10 L, indicating limited extravascular distribution consistent with a large peptide.
Subcutaneous administration: approximately 85% absolute bioavailability compared to intravenous injection.
Subcutaneous administration: Bioavailability is approximately 50% relative to intravenous administration, with absorption characterized by a slow and sustained release profile.
No specific dose adjustment is recommended for patients with renal impairment; however, caution is advised in severe impairment due to limited data.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min). Use with caution.
No specific dose adjustment is recommended for patients with hepatic impairment; however, caution is advised in severe impairment due to limited data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Not indicated for pediatric use; safety and efficacy have not been established.
Safety and efficacy in pediatric patients have not been established. Not indicated for use in children.
Not indicated for geriatric use; safety and efficacy have not been established in women over 65 years.
No specific dose adjustment is recommended for elderly patients. Monitor for cardiovascular events and changes in bone density due to androgen deprivation.
None.
Increased risk of QT interval prolongation; use caution in patients with congenital long QT syndrome, electrolyte abnormalities, or concomitant use of QT-prolonging drugs. Also, hypersensitivity reactions including anaphylaxis have been reported.
Hypersensitivity reactions (e.g., anaphylaxis) have been reported.,Ovarian hyperstimulation syndrome (OHSS) may occur; monitor during stimulation.,Use caution in patients with active allergic conditions or history of asthma.
QT prolongation and ventricular arrhythmias (especially with hypokalemia or bradycardia),Hypersensitivity reactions (urticaria, angioedema, anaphylaxis),Tumor flare reaction (transient worsening of symptoms due to initial testosterone surge) - less common with degarelix compared to Gn RH agonists,Loss of bone mineral density with long-term use,Injection site reactions (pain, erythema, nodule, necrosis),Increased hepatic enzymes (transient and usually asymptomatic),Hyperglycemia and increased risk of diabetes (monitor blood glucose),Cardiovascular risks (myocardial infarction, stroke) in patients with pre-existing conditions
Hypersensitivity to cetrorelix, Gn RH, or any other Gn RH analog.,Known or suspected pregnancy.,Breastfeeding.,Severe renal impairment (creatinine clearance <30 m L/min).,Pre-existing moderate to severe hepatic impairment.
Hypersensitivity to degarelix or any component of the formulation,Women of reproductive potential (pregnancy category X; can cause fetal harm),Severe renal impairment (Cr Cl < 30 m L/min) - insufficient data,Severe hepatic impairment (Child-Pugh class C) - not studied
No known food interactions. No dietary restrictions required.
No significant food interactions. Avoid grapefruit juice if also taking certain antiarrhythmics or other QT-prolonging drugs. Maintain adequate calcium and vitamin D intake if at risk for bone loss.
Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than human exposure. No adequate human studies exist.
FIRMAGON (degarelix) is contraindicated in pregnancy. Gn RH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal studies and its mechanism of action, degarelix is expected to increase the risk of first trimester pregnancy loss. Adequate human data are not available, but the drug should be avoided during pregnancy. If exposure occurs, inform the patient of the potential hazard.
No data on cetrorelix excretion in human milk. M/P ratio unknown. Given its peptide nature and short half-life, excretion is unlikely but not confirmed. Caution advised; avoid use in nursing mothers unless clearly needed.
It is not known whether degarelix is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from degarelix, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Cetrorelix is contraindicated in pregnancy; no dosing adjustments apply. Dose modifications are not recommended as drug should not be used.
No dosage adjustment studies have been conducted in pregnant women. Degarelix is contraindicated in pregnancy, and use should be avoided. If inadvertent exposure occurs, no specific dose adjustment is recommended; instead, the drug should be discontinued and the patient counseled about fetal risks.
Cetrotide (cetrorelix) is a Gn RH antagonist used in controlled ovarian stimulation to prevent premature LH surges. Administer subcutaneously in the lower abdominal wall; rotate sites. Monitor for ovarian hyperstimulation syndrome (OHSS). Onset of action is immediate; does not cause flare effect like Gn RH agonists. Dose adjustment not required in renal or hepatic impairment. Use with caution in patients with allergies to Gn RH analogs or mannitol.
FIRMAGON (degarelix) is a Gn RH antagonist indicated for advanced prostate cancer. It does not cause testosterone flare like Gn RH agonists. Monitor serum calcium in patients with bone metastases due to risk of hypercalcemia. Injection site reactions are common; rotate sites and apply warm compresses. Use with caution in patients with congenital long QT syndrome or those on Class IA/III antiarrhythmics.
Inject exactly as prescribed, at the same time each day during the stimulation cycle.,Do not skip doses; missing a dose may increase risk of premature ovulation.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing.,Mild injection site reactions (redness, swelling, itching) are common and usually resolve.,Avoid pregnancy prior to the procedure; use non-hormonal contraception if needed.,Understand the risk of OHSS: symptoms include severe pelvic pain, nausea, vomiting, sudden weight gain, and decreased urination.
This medication is given as an injection under the skin, usually every month.,It may cause injection site reactions like redness, swelling, or pain; applying a warm compress can help.,You may experience hot flashes, decreased libido, or erectile dysfunction.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or unusual bleeding/bruising.,Regular blood tests are needed to monitor response and side effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CETROTIDE vs FIRMAGON, answered by our medical review team.
CETROTIDE is a GnRH antagonist that works by Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. FIRMAGON is a GnRH Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively binds to Gn RH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CETROTIDE and FIRMAGON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CETROTIDE is: 0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.. The standard adult dose of FIRMAGON is: For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CETROTIDE and FIRMAGON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CETROTIDE is classified as Category C. Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than . FIRMAGON is classified as Category C. FIRMAGON (degarelix) is contraindicated in pregnancy. GnRH antagonists like degarelix can cause fetal harm when administered to a pregnant woman. Based on findings from animal stud. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.